Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer

Girish S. Shroff; Patricia M. de Groot; Vassiliki A. Papadimitrakopoulou; Mylene T. Truong; Brett W. Carter

doi:10.1016/j.rcl.2018.01.012

Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer

Girish S. Shroff, Patricia M. de Groot, Vassiliki A. Papadimitrakopoulou, Mylene T. Truong, Brett W. Carter

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

The treatment strategy in advanced non–small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.

Original language	English (US)
Pages (from-to)	485-495
Number of pages	11
Journal	Radiologic Clinics of North America
Volume	56
Issue number	3
DOIs	https://doi.org/10.1016/j.rcl.2018.01.012
State	Published - May 2018

Keywords

Immunotherapy
Lung cancer
Targeted therapy

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.rcl.2018.01.012

Cite this

@article{c8ee9200d61d4a0b81c5999cf61e94eb,

title = "Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer",

abstract = "The treatment strategy in advanced non–small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.",

keywords = "Immunotherapy, Lung cancer, Targeted therapy",

author = "Shroff, {Girish S.} and {de Groot}, {Patricia M.} and Papadimitrakopoulou, {Vassiliki A.} and Truong, {Mylene T.} and Carter, {Brett W.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = may,

doi = "10.1016/j.rcl.2018.01.012",

language = "English (US)",

volume = "56",

pages = "485--495",

journal = "Radiologic Clinics of North America",

issn = "0033-8389",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer

AU - Shroff, Girish S.

AU - de Groot, Patricia M.

AU - Papadimitrakopoulou, Vassiliki A.

AU - Truong, Mylene T.

AU - Carter, Brett W.

PY - 2018/5

Y1 - 2018/5

N2 - The treatment strategy in advanced non–small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.

AB - The treatment strategy in advanced non–small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.

KW - Immunotherapy

KW - Lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85044740669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044740669&partnerID=8YFLogxK

U2 - 10.1016/j.rcl.2018.01.012

DO - 10.1016/j.rcl.2018.01.012

M3 - Review article

C2 - 29622080

AN - SCOPUS:85044740669

SN - 0033-8389

VL - 56

SP - 485

EP - 495

JO - Radiologic Clinics of North America

JF - Radiologic Clinics of North America

IS - 3

ER -

Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this